CY1107314T1 - Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη - Google Patents

Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη

Info

Publication number
CY1107314T1
CY1107314T1 CY20061101704T CY061101704T CY1107314T1 CY 1107314 T1 CY1107314 T1 CY 1107314T1 CY 20061101704 T CY20061101704 T CY 20061101704T CY 061101704 T CY061101704 T CY 061101704T CY 1107314 T1 CY1107314 T1 CY 1107314T1
Authority
CY
Cyprus
Prior art keywords
classification
patients affected
composite integrity
education
therapeutic
Prior art date
Application number
CY20061101704T
Other languages
English (en)
Inventor
David Martin
Norman L Fischer
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1107314T1 publication Critical patent/CY1107314T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση περιλαμβάνει μεθόδους πρόληψης και θεραπευτικής αγωγής σκλήρυνσης κατά πλάκας χορηγώντας σε ασθενείς χρείζοντες αυτών θεραπευτικά αποτελεσματική ποσότητα IFN-con, μόνη της ή σε συνδυασμό με άλλον δραστικό παράγοντα.
CY20061101704T 1997-08-15 2006-11-27 Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη CY1107314T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EP98933344A EP1003546B1 (en) 1997-08-15 1998-07-15 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon

Publications (1)

Publication Number Publication Date
CY1107314T1 true CY1107314T1 (el) 2012-11-21

Family

ID=25431058

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101704T CY1107314T1 (el) 1997-08-15 2006-11-27 Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη

Country Status (18)

Country Link
US (1) US6013253A (el)
EP (1) EP1003546B1 (el)
JP (1) JP3813440B2 (el)
KR (1) KR100415636B1 (el)
CN (1) CN1183963C (el)
AT (1) ATE338563T1 (el)
AU (1) AU741074B2 (el)
CA (1) CA2299361C (el)
CY (1) CY1107314T1 (el)
DE (1) DE69835823T2 (el)
DK (1) DK1003546T3 (el)
ES (1) ES2267188T3 (el)
HK (1) HK1030157A1 (el)
HU (1) HU229045B1 (el)
IL (2) IL134345A0 (el)
PT (1) PT1003546E (el)
TW (1) TW474817B (el)
WO (1) WO1999008702A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003049761A1 (en) * 2000-12-08 2003-06-19 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
DE60316407T2 (de) * 2002-02-06 2008-06-19 Ares Trading S.A. Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
AU2005244448B2 (en) * 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
BRPI0510526A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
US20100028296A1 (en) * 2005-05-02 2010-02-04 Chavez Raymond A Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
WO2007022799A1 (en) 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
KR20080050591A (ko) * 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EA201070773A1 (ru) * 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US20130017999A1 (en) 2011-07-14 2013-01-17 Marc Fremont Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
WO2015009955A1 (en) 2013-07-18 2015-01-22 Xalud Therapeutics, Inc. Methods for the treatment of inflammatory joint disease
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
ES2103305T3 (es) * 1989-11-29 1997-09-16 Amgen Boulder Inc Produccion de inhibidor de interleuquina-1 humana recombinada.
AU7683391A (en) * 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
AU672606B2 (en) * 1992-04-30 1996-10-10 Amgen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
RO113528B1 (ro) * 1992-09-17 1998-08-28 Synergen Inc Compozitie farmaceutica pentru inhibarea interleukinei-1
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
EP0701563A4 (en) * 1993-03-08 1997-07-02 Univ Pittsburgh GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL
US5932208A (en) * 1993-03-19 1999-08-03 Vacsyn S.A. Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
EP1090645B1 (en) * 1994-02-08 2005-12-07 Amgen Inc., Oral delivery of chemically modified proteins

Also Published As

Publication number Publication date
EP1003546B1 (en) 2006-09-06
KR20010030563A (ko) 2001-04-16
TW474817B (en) 2002-02-01
AU741074B2 (en) 2001-11-22
ES2267188T3 (es) 2007-03-01
CN1183963C (zh) 2005-01-12
HUP0002755A3 (en) 2001-11-28
ATE338563T1 (de) 2006-09-15
WO1999008702A1 (en) 1999-02-25
CN1267225A (zh) 2000-09-20
DE69835823D1 (de) 2006-10-19
HU229045B1 (en) 2013-07-29
PT1003546E (pt) 2006-12-29
DE69835823T2 (de) 2007-08-09
DK1003546T3 (da) 2006-10-30
IL134345A0 (en) 2001-04-30
JP2001515047A (ja) 2001-09-18
CA2299361C (en) 2009-09-29
HK1030157A1 (en) 2001-04-27
HUP0002755A2 (hu) 2000-12-28
EP1003546A1 (en) 2000-05-31
JP3813440B2 (ja) 2006-08-23
CA2299361A1 (en) 1999-02-25
IL134345A (en) 2011-03-31
AU8300698A (en) 1999-03-08
KR100415636B1 (ko) 2004-01-24
US6013253A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
CY1107586T1 (el) Θepαπεiα για τη δυσκοιλιoτητα
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
NO20002785L (no) Adamantanderivater
NO20002786D0 (no) Adamantanderivater
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
DK0680323T3 (da) Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer.
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
CY1105624T1 (el) Αντιγλαυκωματικο μεσο και χρηση αυτου
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa